Impact of Genetic Variants of Apolipoprotein E on Lipid Profile in Patients with Parkinson's Disease

Table 3

Means and standard deviations for lipid profile in patients with Parkinson's disease (PD) and without (Controls) considering APOE polymorphism.

Biochemical profile (mg/dL)	PD (𝑁=232)		Controls (𝑁=137)		P
	APOE-/4 (a); (𝑁=15)	APOE3/3 (b); (𝑁=58)	APOE-/4 (c); (𝑁=19)	APOE3/3 (d); (𝑁=94)
TC
Mean	206.5	203.7	200.7	190.4	0.391^∗
SD	48.7	47.4	59.4	54.5
LDLc
Mean	128.7	121.7	123.1	109.9	0.254^∗
SD	43.3	38.8	55.0	46.1
HLDc
Mean	51.8	60.3	56.5	52.0	𝟎.𝟎𝟎𝟕^∗
SD	10.5	13.3	15.9	15.5	(axb 𝑃=0.012; bxd 𝑃=0.001)^†
VLDLc
Mean	24.3	22.7	22.6	36.3	𝟎.𝟎𝟐𝟒^∗
SD	17.1	13.1	9.0	37.4	(cxd 𝑃=0.001)^†
TG
Mean	126.0	113.3	129.7	143.5	𝟎.𝟎𝟑𝟗^∗
SD	82.5	65.7	83.5	79.8	(bxd 𝑃=0.010)^†

∗One-Way ANOVA Test; ^†t-test; TC: total cholesterol; HDLc: high density lipoprotein cholesterol; LDLc: low density lipoprotein cholesterol; VLDLc: very low density lipoprotein cholesterol; TG: triglycerides; SD: standard deviation; N: number of individuals.